Tomoko Yamaguchi
Tomoko Yamaguchi has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Akira Yamamoto
Department of Biopharmaceutics, Kyoto Pharmaceutical University, Yamashina-ku, Kyoto 607-8414, Japan
1 shared publication Chihiro Naito
Department of Biopharmaceutics, Kyoto Pharmaceutical University
1 shared publication- Chisato Hayashi
Research Institute of Nursing Care for People and Community, University of Hyogo, Akashi, Japan
1 shared publication - Hidemasa Katsumi
Department of Biopharmaceutics, Kyoto Pharmaceutical University, Misasagi, Yamashina-ku, Kyoto 607-8414, Japan
1 shared publication - Junko Honda
Research Institute of Nursing Care for People and Community University of Hyogo Hyogo Japan
1 shared publication - Kayoko Omura
College of Nursing Art and Science, University of Hyogo
1 shared publication
Latest Publications
- Open Access
- 20 February 2025
- Published by Japan Society of Nursing Research in Journal of International Nursing Research
- Vol. 4 (1) , e2023-0037
Impact of the coronavirus disease 2019 (COVID-19) pandemic on children and youth with special needs and their families in Japan and support issues
Objective: To elucidate the impact of the coronavirus disease 2019 (COVID-19) pandemic on children and youth with special needs, their families, and their supporters in Japan. Methods: This qualitative descriptive study was carried out via focus groups. Participants were care providers and family caregivers of children and youth with special needs. In the survey, the participants were asked about the changes in physical and mental health, caregiving status, and multidisciplinary collaboration during the COVID-19 pandemic. Results: The categories of the impact of the COVID-19 pandemic on children and youth with special needs and their families were [Concentration of burden on primary caregivers], [Mental stress of the primary caregiver], [Mental and physical impact on children and youth with special needs], [Dissatisfaction/anxiety about changes in social interactions], [Sibling/family mental stress], and [Increased risk of abuse due to lack of respite]. The problems encountered by service providers during the pandemic included [Difficulty in utilizing social resources], [Disparities in the use of support services and systems], [Problems due to the changes in the way people go to the hospital], [Difficulties in assuring quality of professional care], [Challenges in organizing a pediatric home care team], and [Need to understand a diverse group of children and youth with special needs]. Conclusions: Our data suggest the need for support to replace family caregiving, as the burden is concentrated on the primary caregiver. In the future, a system will be required to promptly respond to the special needs of each child through the collaboration of the government, hospital, and community.
- 20 February 2025
- Published by Japan Society of Nursing Research in Journal of International Nursing Research
- Vol. 4 (1) , e2023-0037
Open AccessImpact of the coronavirus disease 2019 (COVID-19) pandemic on children and youth with special needs and their families in Japan and support issues
Objective: To elucidate the impact of the coronavirus disease 2019 (COVID-19) pandemic on children and youth with special needs, their families, and their supporters in Japan. Methods: This qualitative descriptive study was carried out via focus groups. Participants were care providers and family caregivers of children and youth with special needs. In the survey, the participants were asked about the changes in physical and mental health, caregiving status, and multidisciplinary collaboration during the COVID-19 pandemic. Results: The categories of the impact of the COVID-19 pandemic on children and youth with special needs and their families were [Concentration of burden on primary caregivers], [Mental stress of the primary caregiver], [Mental and physical impact on children and youth with special needs], [Dissatisfaction/anxiety about changes in social interactions], [Sibling/family mental stress], and [Increased risk of abuse due to lack of respite]. The problems encountered by service providers during the pandemic included [Difficulty in utilizing social resources], [Disparities in the use of support services and systems], [Problems due to the changes in the way people go to the hospital], [Difficulties in assuring quality of professional care], [Challenges in organizing a pediatric home care team], and [Need to understand a diverse group of children and youth with special needs]. Conclusions: Our data suggest the need for support to replace family caregiving, as the burden is concentrated on the primary caregiver. In the future, a system will be required to promptly respond to the special needs of each child through the collaboration of the government, hospital, and community.
- Open Access
- 1 January 2021
- Published by Pharmaceutical Society of Japan in Biological and Pharmaceutical Bulletin
- Vol. 44 (1) , 140-143
Human Induced Pluripotent Stem Cell-Based Skin for Assessing Transdermal Drug Permeability and Irritancy
To establish a system for assessing drug permeation and irritation of the skin, the permeation of benzoic acid and isosorbide dinitrate, which are listed in the Pharmacopoeia, and the chemical irritation were evaluated using skin generated from human induced pluripotent stem cells (iPSCs). Multilayer structures and cellular markers (keratin 14 and 10, which are in basal and suprabasal epidermal layers) were clearly detected in our iPSC-based skin. Transepidermal water loss (TEWL) decreased after iPSC-derived keratinocytes were cultured on collagen gels from human primary fibroblasts. These results indicate that the barrier function was partly increased by formation of the living epidermis. The cumulative amount of benzoic acid and isosorbide dinitrate across human iPSC-based skin gradually increased after an initial lag time. Moreover, the irritancy of various chemicals (non-irritants: ultrapure water, allyl phenoxy-acetate, isopropanol, and hexyl salicylate and irritants: 5% sodium dodecyl sulfate (SDS), heptanal, potassium hydroxide (5% aq.) and cyclamen aldehyde) to iPSC-based skin was almost met the irritation criteria of the Organisation for Economic Co-operation and Development (OECD) guideline. The results of our iPSC-based skin evaluation provide useful basic information for developing an assessment system to predict the permeation and safety of new transdermal drugs in human skin.
- 1 January 2021
- Published by Pharmaceutical Society of Japan in Biological and Pharmaceutical Bulletin
- Vol. 44 (1) , 140-143
Open AccessHuman Induced Pluripotent Stem Cell-Based Skin for Assessing Transdermal Drug Permeability and Irritancy
To establish a system for assessing drug permeation and irritation of the skin, the permeation of benzoic acid and isosorbide dinitrate, which are listed in the Pharmacopoeia, and the chemical irritation were evaluated using skin generated from human induced pluripotent stem cells (iPSCs). Multilayer structures and cellular markers (keratin 14 and 10, which are in basal and suprabasal epidermal layers) were clearly detected in our iPSC-based skin. Transepidermal water loss (TEWL) decreased after iPSC-derived keratinocytes were cultured on collagen gels from human primary fibroblasts. These results indicate that the barrier function was partly increased by formation of the living epidermis. The cumulative amount of benzoic acid and isosorbide dinitrate across human iPSC-based skin gradually increased after an initial lag time. Moreover, the irritancy of various chemicals (non-irritants: ultrapure water, allyl phenoxy-acetate, isopropanol, and hexyl salicylate and irritants: 5% sodium dodecyl sulfate (SDS), heptanal, potassium hydroxide (5% aq.) and cyclamen aldehyde) to iPSC-based skin was almost met the irritation criteria of the Organisation for Economic Co-operation and Development (OECD) guideline. The results of our iPSC-based skin evaluation provide useful basic information for developing an assessment system to predict the permeation and safety of new transdermal drugs in human skin.